Dr. Sarah Larson is interested in identifying novel signal pathways and therapeutics for B cell lymphomas and multiple myeloma. She works with the lymphoma and multiple myeloma cell line panels in the Translational Oncology Research Laboratory (TORL) and conducts clinical trials as a member of the Hematologic Malignancies Program and the Lymphoma Program.
Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar;53(3):445-50. doi: 10.3109/10428194.2011.621562.
Larson SM, Godley LA. Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leuk Lymphoma. 2010 Dec;51(12):2147-8. doi: 10.3109/10428194.2010.531802.